ENDRA Life Sciences (NDRA) EBITDA (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported EBITDA for 11 consecutive years, with -$1.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 14.0% year-over-year to -$1.5 million in Q2 2026; TTM through Jun 2026 was -$6.6 million, a 22.46% increase from a year earlier, with the FY2025 full-year figure at -$5.8 million, up 46.72% from the prior year.
• EBITDA was -$1.5 million for Q2 2026 at ENDRA Life Sciences, up from -$2.2 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.3 million in Q2 2025 and troughed at -$4.3 million in Q4 2024.
• A 5-year average of -$2.4 million and a median of -$2.5 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 194.75% in 2024 and soared 62.25% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$3.3 million in 2022, then jumped by 56.0% to -$1.5 million in 2023, then sank by 194.75% to -$4.3 million in 2024, then soared by 62.25% to -$1.6 million in 2025, then grew by 8.56% to -$1.5 million in 2026.
• The last three EBITDA figures came in at -$1.5 million (Q2 2026), -$2.2 million (Q1 2026), and -$1.6 million (Q4 2025), per Business Quant data.